Drug
Dabigatran Etexilate
Dabigatran Etexilate: highest development phase Phase 2, developed by Boehringer Ingelheim, Chiesi Farmaceutici, United Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Boehringer Ingelheim, Chiesi Farmaceutici, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dabigatran etexilate NCT02256683 | Phase 2 | Atrial Fibrillation or Atrial Flutter |
| Dabigatran etexilate NCT02171507 | Phase 1 | Healthy |
| Dabigatran Etexilate NCT07744386 | Phase 1 | Healthy Male Volunteers |
Latest
No recent events.
Follow Dabigatran Etexilate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.